Combined therapy with DR5- targeting antibody-drug conjugate and CDK inhibitors as a novel strategy for advanced MSS and MSI-H colorectal cancer
RNA-seq (gene expression) · human · 24 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Colorectal cancerThis series is part of our curated briefing on it.
- Samples
- 24 samples: 12 × Tumour, Control, 2Day, vs 12 × Tumour, Oba01, 2Day,Groups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Combined therapy with DR5-targeting antibody-drug conjugate and CDK inhibitors as a strategy for advanced colorectal cancerCell reports. Medicine · 2025
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE288560_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1218435 and SRA study SRP561098. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 24 samples.
How we read this: 2 replicated groups read from 24 sample titles; they account for 24 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8769853 Tumour, Control, 2Day, rep1 Tumour, Control, 2Day,
- GSM8769854 Tumour, Control, 2Day, rep2 Tumour, Control, 2Day,
- GSM8769855 Tumour, Control, 2Day, rep3 Tumour, Control, 2Day,
- GSM8769856 Tumour, Oba01, 2Day, rep1 Tumour, Oba01, 2Day,
- GSM8769857 Tumour, Oba01, 2Day, rep2 Tumour, Oba01, 2Day,
- GSM8769858 Tumour, Oba01, 2Day, rep3 Tumour, Oba01, 2Day,
- GSM8769859 Tumour, Control, 2Day, rep4 Tumour, Control, 2Day,
- GSM8769860 Tumour, Control, 2Day, rep5 Tumour, Control, 2Day,
- GSM8769861 Tumour, Control, 2Day, rep6 Tumour, Control, 2Day,
- GSM8769862 Tumour, Oba01, 2Day, rep4 Tumour, Oba01, 2Day,
- GSM8769863 Tumour, Oba01, 2Day, rep5 Tumour, Oba01, 2Day,
- GSM8769864 Tumour, Oba01, 2Day, rep6 Tumour, Oba01, 2Day,
- GSM8769865 Tumour, Control, 2Day, rep7 Tumour, Control, 2Day,
- GSM8769866 Tumour, Control, 2Day, rep8 Tumour, Control, 2Day,
- GSM8769867 Tumour, Control, 2Day, rep9 Tumour, Control, 2Day,
- GSM8769868 Tumour, Oba01, 2Day, rep7 Tumour, Oba01, 2Day,
- GSM8769869 Tumour, Oba01, 2Day, rep8 Tumour, Oba01, 2Day,
- GSM8769870 Tumour, Oba01, 2Day, rep9 Tumour, Oba01, 2Day,
- GSM8769871 Tumour, Control, 2Day, rep10 Tumour, Control, 2Day,
- GSM8769872 Tumour, Control, 2Day, rep11 Tumour, Control, 2Day,
- GSM8769873 Tumour, Control, 2Day, rep12 Tumour, Control, 2Day,
- GSM8769874 Tumour, Oba01, 2Day, rep10 Tumour, Oba01, 2Day,
- GSM8769875 Tumour, Oba01, 2Day, rep11 Tumour, Oba01, 2Day,
- GSM8769876 Tumour, Oba01, 2Day, rep12 Tumour, Oba01, 2Day,
- GSE250000 Bulk RNA-sequencing of transduced colorectal cancer cell line HCT-116 and breast cancer cell line MCF-7 overexpressing full-lenght p53β or p53β-stop-lost. 4 samples same disease briefing · shares colorectal
- GSE12032 Inherent gene signature of stage II and III colorectal cancer leads in individual recurrence 198 samples same disease briefing · shares colorectal
- GSE109308 Single-cell transcriptomic survey of adenomatous polyposis patients with germline APC mutations 97 samples same disease briefing
- GSE110009 Single cell transcriptome landscape of primary and metastatic tumor in colon cancer 76 samples same disease briefing
- GSE289746 Combined therapy with DR5- targeting antibody-drug conjugate and CDK inhibitors as a novel strategy for advanced MSS and MSI-H colorectal cancer 12 samples shares msi-h, dr5, cdk, mss, antibody-drug, inhibitors, colorectal, targeting
- GSE261195 CDKN1B (p27kip1) enhances drug tolerant persister CTCs by restricting polyploidy following mitotic inhibitors. 320 samples shares cdk, inhibitors
- GSE289582 Baseline tumor features and peripheral blood immune dynamics that underlie efficacy in MSS metastatic colorectal cancer treated with regorafenib, ipilimumab, and nivolumab [Blood] 115 samples shares mss, colorectal
- GSE296805 An immunological mechanism of resistance to CDK4/6 inhibitors in breast cancer 50 samples shares cdk, inhibitors
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.